Biohoo Life Science Directory
|
|
CureVac GmbH
By making mRNA available for therapeutic purposes, CureVac seeks to introduce a novel class of drugs into today's medicine. Building on a unique body of knowledge in RNA research, design and cGMP production, the Company has established a range of proprietary technologies. These include: RNActive® for the design of modified and formulated mRNA targeting a broad range of therapeutic applications, RNAdjuvant® for the use of RNA as an immune stimulant, PUREmessenger® for the GMP-production of long-chain mRNA up to 15.000 nt. Based on these technologies, the Company is building a growing pipeline of innovative product candidates. CureVac develops RNActive®-derived vaccines for the treatment of prostate cancer and non-small cell lung cancer (NSCLC). The Phase I trial in prostate cancer began in December 2008; a similar trial in NSCLC will start in 2009. The Company was spun off from Tübingen University in 2000 and has secured approximately €38 million in private equity. Key investor is the dievini Hopp BioTech holding GmbH&Co. KG, a venture capital firm owned by the Hopp family. Mr. Dietmar Hopp is a co-founder of Walldorf-based software house SAP AG. |
Germany
|
|
|
RiNA GmbH
In house, RiNA develops customized RNA aptamers as tools for environmental analytics, as well as for diagnostic and therapeutic approaches. Several aptamer projects are funded by the 6th European Framework Programme and the “Deutsche Bundesstiftung Umwelt”. RiNA has developed cell-free protein synthesis systems (procaryotic and eukaryotic origin) and produces different kits for in vitro protein biosynthesis which are distributed by Qiagen GmbH. In addition, RiNA offers a synthesis service for unmodified and labelled proteins for functional and structural analysis (NMR). |
|
Germany
|
